Anixa Biosciences (ANIX) Net Margin (2010 - 2023)

Anixa Biosciences' (ANIX) quarterly Net Margin came in at 3328.57% in Q2 2023, down 100.82% on a QoQ basis from 407732.5% in Q4 2021.

Anixa Biosciences (ANIX) Net Margin (2010 - 2023) Analysis & Trends

Anixa Biosciences (ANIX) has 11 years of Net Margin data on file, last reported at 3328.57% in Q2 2023.

Quarterly Net Margin changed N/A year-over-year to 3328.57% in Q2 2023, while the trailing twelve-month figure through Oct 2023 was 16519538.28% (changed N/A YoY) and the FY2023 annual result came in at 16434252.38%, changed N/A from the prior year.
Net Margin fell to 3328.57% in Q2 2023, from 407732.5% in the prior quarter.
In the past five years, Net Margin ranged from a high of 407732.5% in Q4 2021 to a low of 3328.57% in Q2 2023.
A 3-year average of 100645.56% and a median of 910.85% in 2019 frame the typical range for Net Margin.
The widest YoY moves for Net Margin: up 83127 bps in 2019, down 83127 bps in 2019.
Tracing ANIX's Net Margin over 3 years: stood at 1015.08% in 2019, then soared by 40268 bps to 407732.5% in 2021, then tumbled by 101 bps to 3328.57% in 2023.
The last three Net Margin figures came in at 3328.57% (Q2 2023), 407732.5% (Q4 2021), and 806.63% (Q1 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	138.93 Bn	131.07 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	85.91 Bn	77.92 Bn	3.93 Bn	30.23%
3	Argenx Se	64.98 Bn	59.80 Bn	1.37 Bn	31.16%
4	Moderna	58.86 Bn	53.72 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	42.03 Bn	36.93 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.54 Bn	28.23 Bn	992.69 Mn	12.74%
7	BioNTech SE	27.88 Bn	9.49 Bn	668.28 Mn	-16.51%
8	Insmed	27.44 Bn	26.28 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.35 Bn	26.51 Bn	-	12.09%
10	Anixa Biosciences	124.96 Mn	124.96 Mn	-	-

Download Data